0001193125-26-118550
SEC filingXilio Therapeutics, Inc., a clinical-stage biotech firm, reported total revenue of $43.8 million for FY 2025, a significant increase from $6.3 million in FY 2024, driven by collaboration and license revenue from agreements with AbbVie ($20.1 million) and Gilead ($23.6 million), including milestones. This marked a YoY revenue growth of approximately 591%. Operating expenses rose to $85.7 million from $66.9 million, reflecting higher R&D ($56.0 million vs $41.2 million) due to clinical advancements in vilastobart, efarindodekin alfa, and XTX501, and G&A ($29.7 million vs $24.8 million). Loss from operations narrowed to -$42.0 million from -$60.6 million. Net loss improved to -$35.0 million from -$58.2 million, aided by a $5.8 million gain from changes in common stock warrant liabilities and $1.1 million other income. Basic and diluted EPS was -$4.00 per share on 8.4 million weighted average shares. Balance sheet strengthened with cash and equivalents at $137.5 million (up from $55.3 million), total assets $154.7 million, and stockholders' equity $35.3 million. Net cash used in operations was -$5.0 million vs -$18.4 million YoY, with financing providing $87.8 million mainly from warrant offerings. Management states cash sufficient through end-2027, excluding milestones, supporting pipeline advancement without near-term dilution needs.
Xilio Therapeutics reported FY2025 revenue of $43.8M, up 591% YoY from $6.3M in FY2024, entirely from collaborations with AbbVie and Gilead. Net loss narrowed to -$35.0M from -$58.2M, driven by revenue growth and $6.9M other income (including $5.8M warrant fair value gain). Operating loss improved to -$42.0M from -$60.6M despite 28% higher expenses ($85.7M vs $66.9M). Cash position strengthened to $137.5M (end-2025), supporting runway through 2027. Shares outstanding: 4.53M issued/outstanding.
All $43.8M revenue from collaborations: AbbVie $20.1M (cumulative catch-up $2.4M on milestone), Gilead $23.6M (catch-up $7.0M on $17.5M milestone). No product sales. Deferred revenue $60.7M ($40.0M current). YoY surge reflects AbbVie deal (Feb 2025) and Gilead milestones.
No gross profit (R&D-focused). Operating margin N/A; loss from ops -$42.0M. R&D $56.0M (up 36% YoY: vilastobart -$0.6M, efarindodekin +$2.7M, XTX501 $9.5M new). G&A $29.7M (up 20%). Restructuring $0.9M in 2024 (none 2025). Warrant gain boosted net.
Operating cash -$5.0M (vs -$18.4M YoY), aided by $49.1M AbbVie + $17.5M Gilead inflows. Investing -$0.5M (capex). Financing +$87.8M (June warrants $47.0M net + $35.8M exercises). Cash $137.5M; total assets $154.7M (current $145.0M). Liabilities $119.4M (warrants $29.6M, deferred rev $60.6M). Equity $35.3M.
Cash funds ops through 2027 (ex-milestones). Pipeline: XTX501 IND mid-2026, Phase 1 H2 2026; PSMA/STEAP1, CLDN18.2 INDs 2027. AbbVie/Gilead milestones possible. Risks: clinical delays, dilution needs.